Patents by Inventor Marc A. Blouin

Marc A. Blouin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Handheld, underwater suction sampler
    Patent number: 9921139
    Abstract: A portable, hand-held sampler for collection of aquatic biotic samples. A pump with an exhaust tube and a water intake tube is attached to a frame. A battery is attached to the frame and electrically connected to the pump. A handle is attached to the bottom of the frame for an operator to hold the sampler in one hand. A switch is electrically connected to the pump and to the battery and attached to the frame near the handle for the operator to control activation of the pump with the same single hand. A venturi tube assembly with a sample intake tube is attached to the exhaust tube. The pump draws water into the water intake tube and sample material into the sample intake tube and the venturi tube diverts the sample material away from the pump and into a sample collection reservoir to prevent damage to the sample material.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: March 20, 2018
    Assignee: The United States of America as Represented by the Secretary of the Department of the Interior
    Inventor: Marc A. Blouin
  • Imidazolyl analogs as syk inhibitors
    Patent number: 9487504
    Abstract: The present invention provides novel imidazole analogs of Formula I which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD, rheumatoid arthritis, and cancer.
    Type: Grant
    Filed: June 18, 2013
    Date of Patent: November 8, 2016
    Assignees: Merck Sharp & Dohme Corp., Merck Canada Inc.
    Inventors: Jongwon Lim, Michael H. Reutershan, John Michael Ellis, Kaleen Konrad Childers, Anthony Donofrio, Michael D. Altman, Andrew M. Haidle, Anna Zabierek, Matthew Christopher, Jonathan Grimm, Jason Burch, Maria Emilia Di Francesco, Alessia Petrocchi, Christian Beaulieu, Vouy Linh Truong, Alan B. Northrup, Marc Blouin
  • Substituted pyridine spleen tyrosine kinase (SYK) inhibitors
    Patent number: 9376418
    Abstract: The invention provides certain substituted pyridines of the Formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, Rcy, Cy, and t are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: June 28, 2016
    Assignees: Merck Sharp & Dohme Corp., Merck Canada Inc.
    Inventors: Andrew M. Haidle, Sandra Lee Knowles, Solomon D. Kattar, Denis Deschenes, Jason Burch, Joel Robichaud, Matthew Christopher, Michael D. Altman, James P. Jewell, Alan B. Northrup, Marc Blouin, John Michael Ellis, Hua Zhou, Christian Fischer, Adam J. Schell, Michael H. Reutershan, Brandon M. Taoka, Anthony Donofrio
  • IMIDAZOLYL ANALOGS AS SYK INHIBITORS
    Publication number: 20150175575
    Abstract: The present invention provides novel imidazole analogs of Formula I which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD, rheumatoid arthritis, and cancer.
    Type: Application
    Filed: June 18, 2013
    Publication date: June 25, 2015
    Inventors: Jongwon Lim, Michael H. Reutershan, John Michael Ellis, Kaleen Konrad Childers, Anthony Donofrio, Michael D. Altman, Andrew M. Haidle, Anna Zabierek, Matthew Christopher, Jonathan Grimm, Jason Burch, Maria Emilia Di Francesco, Alessia Petrocchi, Christian Beaulieu, Vouy Linh Truong, Alan B. Northrup, Marc Blouin
  • SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS
    Publication number: 20150148327
    Abstract: The invention provides certain substituted pyridines of the Formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, Rcy, Cy, and t are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.
    Type: Application
    Filed: June 17, 2013
    Publication date: May 28, 2015
    Applicant: Merck Canada Inc.
    Inventors: Andrew M. Haidle, Sandra Lee Knowles, Solomon D. Kattar, Denis Deschenes, Jason Burch, Joel Robichaud, Matthew Christopher, Michael D. Altman, James P. Jewell, Alan B. Northrup, Marc Blouin, John Michael Ellis, Hua Zhou, Christian Fischer, Adam J. Schell, Michael H. Reutershan, Brandon M. Taoka, Anthony Donofrio, Joel Robichaud
  • Thiophenecarboxamide derivatives as EP4 receptor ligands
    Patent number: 8969394
    Abstract: The invention is directed to thiophenecarboxamide derivatives of formulae I and II as EP4 receptor ligands, antagonists or agonists, useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis, cancer and glaucoma. Pharmaceutical compositions and methods of use are also included. (Formulas I and II).
    Type: Grant
    Filed: August 10, 2007
    Date of Patent: March 3, 2015
    Assignee: Merck Frosst Canada Ltd.
    Inventors: Marc Blouin, Jason Burch, Yongxin Han, Christophe Mellon
  • THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS
    Publication number: 20090247596
    Abstract: The invention is directed to thiophenecarboxamide derivatives of formulae I and II as EP4 receptor ligands, antagonists or agonists, useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis, cancer and glaucoma. Pharmaceutical compositions and methods of use are also included. (Formulas I and II).
    Type: Application
    Filed: August 10, 2007
    Publication date: October 1, 2009
    Inventors: Marc Blouin, Jason Burch, Yongxin Han, Christophe Mellon
  • Novel Pharmaceutical Compounds
    Publication number: 20090227638
    Abstract: The instant invention provides compounds of Formula (Ia) which are leukotriene biosynthesis inhibitors, wherein X is O or S, Y is O, S, —NR6—CHR7— or —NR8—C(O)— and A is selected from 5-membered aromatic heterocyclic ring, 6-membered aromatic heterocyclic ring, naphthelenic or heterobicyclic aromatic ring system, phenyl and benzyl. A is optionally mono- or disubstituted. Compounds of Formula (Ia) are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.
    Type: Application
    Filed: March 21, 2006
    Publication date: September 10, 2009
    Inventors: Marc Blouin, Erich L. Grimm, Yves Gareau, Marc Gagnon, Helene Juteau, Sebastien Laliberte, Bruce MacKay, Richard Friesen
  • Pharmaceutical compounds
    Patent number: 7553973
    Abstract: The instant invention provides compounds of Formula Ia which are leukotriene biosynthesis inhibitors. Compounds of Formula Ia are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.
    Type: Grant
    Filed: March 21, 2006
    Date of Patent: June 30, 2009
    Assignee: Merck Frosst Canada Ltd.
    Inventors: Marc Blouin, Erich L. Grimm, Yves Gareau, Marc Gagnon, Helene Juteau, Sebastien Laliberte, Bruce MacKay, Richard Friesen
  • Novel pharmaceutical compounds
    Publication number: 20090030048
    Abstract: The instant invention provides compounds of Formula Ia which are leukotriene biosynthesis inhibitors. Compounds of Formula Ia are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.
    Type: Application
    Filed: June 27, 2008
    Publication date: January 29, 2009
    Inventors: Marc Blouin, Erich L. Grimm, Yves Gareau, Marc Gagnon, Helene Juteau, Sebastien Laliberte, Bruce MacKay, Richard Friesen
  • 7-(1,3-thiazol-2-YL)thio-coumarin derivatives and their use as leukotriene biosynthesis inhibitors
    Patent number: 7439260
    Abstract: The instant invention provides compounds of Formula (I) which are leukotriene biosynthesis inhibitors. Compounds of formula (I) are useful as anti-asthmatic, anti-allergic, anti-inflammatory, cytoprotective and anti-artherosclerotic agents.
    Type: Grant
    Filed: June 8, 2004
    Date of Patent: October 21, 2008
    Assignee: Merck Forsst Canada & Co.
    Inventors: Yves Gareau, Helene Juteau, D. Bruce MacKay, Richard Friesen, Erich L. Grimm, Marc Blouin, Sebastien Laliberte
  • Novel pharmaceutical compounds
    Publication number: 20070149579
    Abstract: The instant invention provides compounds of Formula Ia which are leukotriene biosynthesis inhibitors. Compounds of Formula Ia are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.
    Type: Application
    Filed: March 21, 2006
    Publication date: June 28, 2007
    Inventors: Marc Blouin, Erich Grimm, Yves Gareau, Marc Gagnon, Helene Juteau, Sebastien Laliberte, Bruce MacKay, Richard Friesen
  • 7-(1,3-thiazol-2-yl)thio!-coumarin derivatives and their use as leukotriene biosynthesis inhibitors
    Publication number: 20060116406
    Abstract: The instant invention provides compounds of Formula (I) which are leukotriene biosynthesis inhibitors. Compounds of formula (I) are useful as anti-asthmatic, anti-allergic, anti-inflammatory, cytoprotective and anti-artherosclerotic agents.
    Type: Application
    Filed: June 8, 2004
    Publication date: June 1, 2006
    Inventors: Yves Gareau, Helene Juteau, D. Bruce MacKay, Richard Friesen, Erich Grimm, Marc Blouin, Sebastien Laliberte
  • Use of phosphodiesterase-4 inhibitors as enhancers of cognition
    Publication number: 20060040981
    Abstract: The present invention is directed to a method of enhancing cognition in a healthy subject comprising administering a safe cognition enhancing amount of a phosphodiesterase-4 inhibitor. In particular, this invention is directed to a method of enhancing memory, learning, retention, recall, awareness and judgement in health subjects comprising administering a safe and effective amount of a phosphodiesterase-4 inhibitor.
    Type: Application
    Filed: November 19, 2003
    Publication date: February 23, 2006
    Inventors: Daniel Dube, Michel Gallant, Patrick Lacombe, Yves Girard, Dwight Macdonald, Richard Friesen, Yves Ducharme, Bernard Cote, Marc Blouin, Evelyn Martins, Daniel Guay, Pierre Hamel, Mario Girard, Richard Frenette, Sebastien Laliberte, Annette Robichaud, Anthony Mastracchio, Helene Perrier
  • Tri-aryl-substituted-ethane PDE4 inhibitors
    Patent number: 6841564
    Abstract: Novel ethanes substituted with i) a phenyl, ii) a thiazole, and iii) a pyridyl moiety are PDE4 inhibitors.
    Type: Grant
    Filed: March 20, 2002
    Date of Patent: January 11, 2005
    Assignee: Merck Frosst Canada & Co.
    Inventors: Richard Freisen, Yves Ducharme, Bernard Cote, Marc Blouin, Evelyn Martins, Daniel Guay, Pierre Hamel, Mario Girard, Richard Frenette, Sebastien Laliberte
  • Tri-aryl-substituted-ethane PDE4 inhibitors
    Publication number: 20020173661
    Abstract: Novel ethanes substituted with i) a phenyl, ii) a thiazole, and iii) a pyridyl moiety are PDE4 inhibitors.
    Type: Application
    Filed: March 20, 2002
    Publication date: November 21, 2002
    Applicant: Merck Frosst Canada & Co.
    Inventors: Richard Freisen, Yves Ducharme, Bernard Cote, Marc Blouin, Evelyn Martins, Daniel Guay, Pierre Hamel, Mario Girard, Richard Frenette, Sebastien Laliberte
  • Tri-aryl-substituted-ethane PDE4 inhibitors
    Patent number: 6399636
    Abstract: Novel ethanes substituted with i) a phenyl, ii) a thiazole, and iii) a pyridyl moiety are PDE4 inhibitors.
    Type: Grant
    Filed: March 16, 2001
    Date of Patent: June 4, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Richard Freisen, Yves Ducharme, Bernard Cote, Marc Blouin, Evelyn Martins, Daniel Guay, Pierre Hamel, Mario Girard, Richard Frenette, Sebastien Laliberte
  • Tri-aryl-substituted-ethane PDE4 inhibitors
    Publication number: 20020013347
    Abstract: Novel ethanes substituted with i) a phenyl, ii) a thiazole, and iii) a pylidyl moiety are PDE4 inhibitors.
    Type: Application
    Filed: March 16, 2001
    Publication date: January 31, 2002
    Inventors: Richard Freisen, Yves Ducharme, Bernard Cote, Marc Blouin, Evelyn Martins, Daniel Guay, Pierre Hamel, Mario Girard, Richard Frenette, Sebastien Laliberte
  • PDE IV inhibiting compounds, compositions and methods of treatment
    Patent number: 6204275
    Abstract: The invention encompasses compounds of Formula I useful in the treatment of diseases, including asthma, by raising the level of cyclic adenosine-3′,5′-monophosphate (cAMP) through the inhibition of phosphodiesterase IV (PDE IV). The invention also encompasses certain pharmaceutical compositions and methods for treatment of diseases by inhibition of PDE IV, resulting in an elevation of cAMP, comprising the use of compounds of Formula I.
    Type: Grant
    Filed: February 25, 2000
    Date of Patent: March 20, 2001
    Assignee: Merck Frosst Canada & Co.
    Inventors: Richard Friesen, Yvbes Ducharme, Daniel Dube, Yves Girard, Richard Frenette, Chun Li, Marc Blouin, Nathalie Chauret, Laird Trimble
  • Heterosubstituted pyridine derivatives as PDE4 inhibitors
    Patent number: 6200993
    Abstract: The invention encompasses the novel compound of Formula I useful in the treatment of diseases, including asthma, by raising the level of cyclic adenosine-3′,5′-monophosphate (cAMP) through the inhibition of phosphodiesterase IV (PDE 4). or a pharmaceutically acceptable salt or hydrate thereof. The invention also encompasses pharmaceutical compositions and methods for treatment.
    Type: Grant
    Filed: April 17, 2000
    Date of Patent: March 13, 2001
    Assignee: Merck Frosst Canada & Co.
    Inventors: Bernard Cote, Richard Friesen, Richard Frenette, Mario Girard, Yves Girard, Cedrickx Godbout, Daniel Guay, Pierre Hamel, Marc Blouin, Yves Ducharme, Sylvie Prescott